Understanding the switchbacks: The impact of direct antivirals on the minimization of hepatitis C virus recurrence after transplantation
David Mutimer – 10 August 2012 – Key Points
Reply:
Ashley M. Lakner, Nury M. Steuerwald, Laura W. Schrum – 10 August 2012
Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow, not increased ammonia uptake
Gitte Dam, Susanne Keiding, Ole L. Munk, Peter Ott, Hendrik Vilstrup, Lasse K. Bak, Helle S. Waagepetersen, Arne Schousboe, Michael Sørensen – 10 August 2012 – Studies have shown decreased cerebral oxygen metabolism (CMRO2) and blood flow (CBF) in patients with cirrhosis with hepatic encephalopathy (HE). It remains unclear, however, whether these disturbances are associated with HE or with cirrhosis itself and how they may relate to arterial blood ammonia concentration and cerebral metabolic rate of blood ammonia (CMRA).
Hepatitis B surface antigen (HBsAg) levels in the prediction of spontaneous HBsAg seroclearance
Yi‐Cheng Chen – 10 August 2012
Practice guidelines on NAFLD
Melissa Palmer – 10 August 2012
Spontaneous clearance of hepatitis C virus in an interleukin 28B favorable genotype highly prevalent area
Chao‐Hung Hung, Kuo‐Chin Chang, Sheng‐Nan Lu, Jing‐Houng Wang, Chien‐Hung Chen, Chuan‐Mo Lee, Tsung‐Hui Hu – 10 August 2012
Yes‐associated protein regulates the hepatic response after bile duct ligation
Haibo Bai, Nailing Zhang, Yang Xu, Qian Chen, Mehtab Khan, James J. Potter, Suresh K. Nayar, Toby Cornish, Gianfranco Alpini, Steven Bronk, Duojia Pan, Robert A. Anders – 8 August 2012 – Human chronic cholestatic liver diseases are characterized by cholangiocyte proliferation, hepatocyte injury, and fibrosis. Yes‐associated protein (YAP), the effector of the Hippo tumor‐suppressor pathway, has been shown to play a critical role in promoting cholangiocyte and hepatocyte proliferation and survival during embryonic liver development and hepatocellular carcinogenesis.
Quality of life after living donor liver transplantation: What we have learned and how we can do better
Leona Kim‐Schluger, Sander Florman – 6 August 2012
Risk of cytomegalovirus disease in high‐risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and meta‐analysis
Andre C. Kalil, Cezarina Mindru, Jean F. Botha, Wendy J. Grant, David F. Mercer, Marco A. Olivera, Megan A. McCartan, Timothy M. McCashland, Alan N. Langnas, Diana F. Florescu – 6 August 2012 – Valganciclovir (VGC) was approved by the Food and Drug Administration in 2004 as cytomegalovirus (CMV) prophylaxis except for liver transplant recipients because of their high incidence of CMV disease with this drug. However, surveys have shown its common off‐label use for CMV prophylaxis in liver transplant recipients.